Illumina (ILMN) News Today

Illumina, Inc. (ILMN) shares rose after the company delivered better‐than‐expected second‐quarter earnings, raised its full‐year guidance and received several price‐target upgrades, though a few analysts remain cautious on its outlook.

• Positive Sentiment: RBC Capital Markets raised its price target to $126 from $118 and reiterated an “Outperform” rating, implying about 33% upside. Benzinga
• Positive Sentiment: Illumina beat Q2 non-GAAP EPS estimates at $1.19 vs. $1.02 consensus and raised its FY2025 EPS guidance to $4.45–$4.55, above the $4.227 consensus. Press Release
• Positive Sentiment: Baird and Canaccord both lifted their price targets on ILMN following upbeat Q2 results. GuruFocus GuruFocus
• Neutral Sentiment: Q2 revenue declined 3% year-over-year to $1.06 billion, missing the $1.12 billion consensus, while non‐GAAP operating margins held at 23.8%. Quarterly Report
• Neutral Sentiment: The company repurchased 4.5 million shares for $380 million at an $84.66 average and agreed to acquire SomaLogic, subject to regulatory approval in H1 2026. PR Newswire
• Negative Sentiment: Barclays raised its target to $90 but kept an “Underweight” rating, signaling about 5% downside. Benzinga
• Negative Sentiment: Bank of America reiterated a “Sell” rating on strategic concerns, even as it nudged its price objective up to $75. TipRanks